目的分析儿童复发性眩晕(recurrent vertigo of children,RVC)患儿的各项相关客观检查结果,试图寻找出有意义的客观检查方法。方法选取RVC患儿50例(眩晕发作组29例,眩晕不发作组21例)和非RVC正常对照组儿童20例,所有入组人员行相关客观...目的分析儿童复发性眩晕(recurrent vertigo of children,RVC)患儿的各项相关客观检查结果,试图寻找出有意义的客观检查方法。方法选取RVC患儿50例(眩晕发作组29例,眩晕不发作组21例)和非RVC正常对照组儿童20例,所有入组人员行相关客观检查,包括位置试验、vHIT、头颅MRI、纯音测听或游戏测听、声导抗、高刺激率ABR、脑电图、脉搏氧及PSG检查,分析各项检查结果,比较RVC组及对照组之间的特征性差异。结果①RVC组脉搏氧异常率、高刺激率ABR异常率及AHI异常率均高于对照组,有统计学差异(均为P<0.05);②眩晕发作组脉搏氧异常率、高刺激率ABR异常率高于眩晕不发作组,有统计学差异(P<0.05);③RVC组和正常对照组的纯音听阈(或游戏测听)、声导抗、颅脑MRI、位置试验检查、vHIT均正常。结论连续睡眠脉搏氧、高刺激率ABR与RVC,尤其是眩晕发作期的RVC具有一定的相关性。AHI与RVC有一定相关性,但与眩晕是否处于发作期没有相关性。连续睡眠脉搏氧监测、PSG、高刺激率ABR可作为诊断RVC的辅助检查。展开更多
Objective There is a large population of patients classified as complex higher-risk and indicated patients(CHIPs)in China with a poor prognosis.The treatment of these patients is complex and challenging,especially whe...Objective There is a large population of patients classified as complex higher-risk and indicated patients(CHIPs)in China with a poor prognosis.The treatment of these patients is complex and challenging,especially when acute cardiac events occur,such as acute coronary syndrome(ACS)or heart failure.Pharmacotherapy and some mechanical circulatory support(MCS)therapeutic devices can provide stable hemodynamic support for CHIPs-percutaneous coronary intervention(PCI).LDL-C is an important pathogenic factor in atherosclerosis,and the target of blood lipid control.Recent studies have revealed that lipoprotein(a)[Lp(a)],which is formed when a covalent bond between apolipoprotein(a)and apolipoprotein B-100 is made,produces an LDL-like particle.This particle is an independent risk factor for the development of atherosclerosis,and is closely correlated to stent thrombosis and restenosis.Furthermore,this requires active intervention.PCSK9 inhibitors have been used in lipid-lowering treatment,and preventing atherosclerosis.The present study explores the efficacy of PCSK9 inhibitors in CHIPs-ACS,and the association between the change in Lp(a)and survival after 2 years of follow-up.Methods The present real-world,prospective control study enrolled 321 CHIPs-ACS who underwent emergency PCI from August 2019 to November 2020,and these patients were followed up for 2 years.These patients were divided into two groups:PCSK9 group(n=161)given the combined PCSK9 inhibitor(140 mg of evolocumab every 2 weeks)and statins-based therapy,and SOC group(n=160)treated with statin-based lipid-lowering therapy alone.Then,the change in lipid index was measured,and the cardiovascular(CV)event recurrence rate was evaluated after one month and 2 years.Afterwards,the contribution of serum lipid parameters,especially the Lp(a)alteration,in patients with earlier initiation of the PCSK9 inhibitor to the CV outcome was analyzed.Results The LDL-C level was significantly reduced in both groups:52.3%in the PCSK9 group and 32.3%(P<0.001)in the SOC group.It is noteworthy that the Lp(a)level decreased by 13.2%in the PCSK9 group,but increased by 30.3%in the SOC group(P<0.001).Furthermore,the number of CV events was not significantly different between the PCSK9 and SOC groups after the 2-year follow-up period.In the PCSK9 group,the Lp(a)reduction was associated with the baseline Lp(a)levels of the patients(r2=−0.315,P<0.001).Moreover,the decrease in Lp(a)contributed to the decline in CV events in patients who received ACS CHIPs-PCI,and the decrease in Lp(a)level was independent of the LDL-C level reduction.Conclusion The early initiation of PCSK9 inhibitors can significantly reduce the LDL-C and Lp(a)levels in ACS CHIPs-PCI.However,further studies are needed to confirm whether PCSK9 inhibitors can reduce the incidence of CV disease in CHIPs.展开更多
文摘目的分析儿童复发性眩晕(recurrent vertigo of children,RVC)患儿的各项相关客观检查结果,试图寻找出有意义的客观检查方法。方法选取RVC患儿50例(眩晕发作组29例,眩晕不发作组21例)和非RVC正常对照组儿童20例,所有入组人员行相关客观检查,包括位置试验、vHIT、头颅MRI、纯音测听或游戏测听、声导抗、高刺激率ABR、脑电图、脉搏氧及PSG检查,分析各项检查结果,比较RVC组及对照组之间的特征性差异。结果①RVC组脉搏氧异常率、高刺激率ABR异常率及AHI异常率均高于对照组,有统计学差异(均为P<0.05);②眩晕发作组脉搏氧异常率、高刺激率ABR异常率高于眩晕不发作组,有统计学差异(P<0.05);③RVC组和正常对照组的纯音听阈(或游戏测听)、声导抗、颅脑MRI、位置试验检查、vHIT均正常。结论连续睡眠脉搏氧、高刺激率ABR与RVC,尤其是眩晕发作期的RVC具有一定的相关性。AHI与RVC有一定相关性,但与眩晕是否处于发作期没有相关性。连续睡眠脉搏氧监测、PSG、高刺激率ABR可作为诊断RVC的辅助检查。
基金the Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University(No.ZNLH-201907)the Hubei Province Health and Family Planning Scientific Research Project(No.WJ2019Q041)the Chinese Academy of Medical Science Innovation Fund for Medical Sciences(No.2021-I2M-1-009).
文摘Objective There is a large population of patients classified as complex higher-risk and indicated patients(CHIPs)in China with a poor prognosis.The treatment of these patients is complex and challenging,especially when acute cardiac events occur,such as acute coronary syndrome(ACS)or heart failure.Pharmacotherapy and some mechanical circulatory support(MCS)therapeutic devices can provide stable hemodynamic support for CHIPs-percutaneous coronary intervention(PCI).LDL-C is an important pathogenic factor in atherosclerosis,and the target of blood lipid control.Recent studies have revealed that lipoprotein(a)[Lp(a)],which is formed when a covalent bond between apolipoprotein(a)and apolipoprotein B-100 is made,produces an LDL-like particle.This particle is an independent risk factor for the development of atherosclerosis,and is closely correlated to stent thrombosis and restenosis.Furthermore,this requires active intervention.PCSK9 inhibitors have been used in lipid-lowering treatment,and preventing atherosclerosis.The present study explores the efficacy of PCSK9 inhibitors in CHIPs-ACS,and the association between the change in Lp(a)and survival after 2 years of follow-up.Methods The present real-world,prospective control study enrolled 321 CHIPs-ACS who underwent emergency PCI from August 2019 to November 2020,and these patients were followed up for 2 years.These patients were divided into two groups:PCSK9 group(n=161)given the combined PCSK9 inhibitor(140 mg of evolocumab every 2 weeks)and statins-based therapy,and SOC group(n=160)treated with statin-based lipid-lowering therapy alone.Then,the change in lipid index was measured,and the cardiovascular(CV)event recurrence rate was evaluated after one month and 2 years.Afterwards,the contribution of serum lipid parameters,especially the Lp(a)alteration,in patients with earlier initiation of the PCSK9 inhibitor to the CV outcome was analyzed.Results The LDL-C level was significantly reduced in both groups:52.3%in the PCSK9 group and 32.3%(P<0.001)in the SOC group.It is noteworthy that the Lp(a)level decreased by 13.2%in the PCSK9 group,but increased by 30.3%in the SOC group(P<0.001).Furthermore,the number of CV events was not significantly different between the PCSK9 and SOC groups after the 2-year follow-up period.In the PCSK9 group,the Lp(a)reduction was associated with the baseline Lp(a)levels of the patients(r2=−0.315,P<0.001).Moreover,the decrease in Lp(a)contributed to the decline in CV events in patients who received ACS CHIPs-PCI,and the decrease in Lp(a)level was independent of the LDL-C level reduction.Conclusion The early initiation of PCSK9 inhibitors can significantly reduce the LDL-C and Lp(a)levels in ACS CHIPs-PCI.However,further studies are needed to confirm whether PCSK9 inhibitors can reduce the incidence of CV disease in CHIPs.
